지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.6
- 수록면
- 63 - 71 (9page)
이용수
초록· 키워드
오류제보하기
Objectives：The aim of this study was to investigate the effect of the clinical and demographic variables such as body weight, dosage, family history of attention-deficit hyperactivity disorder (ADHD), and psychiatric co-morbidity on the side-effects of OROS-Methylphenidate (OROS-MPH), and to evaluate the relationship between drug response and side effect severity.
Methods：A total of 144 children (ages 6-18) with diagnosed ADHD were treated with OROS-MPH. Children were examined at baseline and after 1, 3, 6, 9, and 12 weeks of each treatment condition. The stimulant drug side effect rating scale (SERS), pulse rate, systolic blood pressure, diastolic blood pressure, and electrocardiogram (ECG) were evaluated to assess side effect profiles. Changes in these parameters from baseline were examined and analyzed.
Results：Anorexia (30.95%) and insomnia (13.10%) were the most commonly reported side effects during this study. Insomnia and loss of appetite score increased at one week follow-up, but was sustained or decreased as treatment progressed. Small but significant increases in pulse rate and diastolic blood pressure were observed during treatment；however, no clinically meaningful changes in ECG parameters were noted during the study. Low body weight, high dosage of OROS-MPH, and family history of ADHD were associated with cardiovascular side effect. In contrast, there was no significant relationship between OROS-MPH treatment response and the severity of side effect and no difference resulted between the responder and non-responder groups with respect to OROS-MPH dosage in the 12 weeks of follow-up.
Conclusion：To the best of our knowledge, this study is the first Korean study to investigate comprehensive side effect profiles and their correlates in OROS-MPH treatment for ADHD children. OROS-MPH was well tolerated with no clinically significant side effects during the treatment period. In conclusion, low body weight, high dosage of OROSMPH, and family history of ADHD could be used as predictive factors in increasing pulse rate and blood pressure.
Methods：A total of 144 children (ages 6-18) with diagnosed ADHD were treated with OROS-MPH. Children were examined at baseline and after 1, 3, 6, 9, and 12 weeks of each treatment condition. The stimulant drug side effect rating scale (SERS), pulse rate, systolic blood pressure, diastolic blood pressure, and electrocardiogram (ECG) were evaluated to assess side effect profiles. Changes in these parameters from baseline were examined and analyzed.
Results：Anorexia (30.95%) and insomnia (13.10%) were the most commonly reported side effects during this study. Insomnia and loss of appetite score increased at one week follow-up, but was sustained or decreased as treatment progressed. Small but significant increases in pulse rate and diastolic blood pressure were observed during treatment；however, no clinically meaningful changes in ECG parameters were noted during the study. Low body weight, high dosage of OROS-MPH, and family history of ADHD were associated with cardiovascular side effect. In contrast, there was no significant relationship between OROS-MPH treatment response and the severity of side effect and no difference resulted between the responder and non-responder groups with respect to OROS-MPH dosage in the 12 weeks of follow-up.
Conclusion：To the best of our knowledge, this study is the first Korean study to investigate comprehensive side effect profiles and their correlates in OROS-MPH treatment for ADHD children. OROS-MPH was well tolerated with no clinically significant side effects during the treatment period. In conclusion, low body weight, high dosage of OROSMPH, and family history of ADHD could be used as predictive factors in increasing pulse rate and blood pressure.
목차
서론
방법
결과
고찰
결론
References
참고문헌 (31)
참고문헌 신청
1. [학술지(정기간행물)] - Elia J / 1993 / Drug treatment for hyperactive children. Therapeutic guidelines / Drugs 46 : 863 ~ 871
2. [학술지(정기간행물)] - Anon / 2002 / Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults / J Am Acad Child Adolesc Psychiatry 41 : 26 ~ 49
3. [학술지(정기간행물)] - Wilens T / 2003 / ADHD treatment with once-daily OROS methylphenidate:interim 12-month results from a long-term open-label study / J Am Acad Child Adolesc Psychiatry 42 : 424 ~ 433
4. [학술지(정기간행물)] - Kelly KL / 1988 / Attention deficit disorder and methylphenidate-a multi-step analysis of dose-response effects on childrens cardiovascular functioning / Int Clin Psychopharmacol 3 : 167 ~ 181
5. [학술지(정기간행물)] - Solanto MV / 1982 / A dose-response and time-action analysis of autonomic and behavioral-effects of methylphenidate in attention deficit disorder with hyperactivity / Psychophysiology 19 : 658 ~ 667
2. [학술지(정기간행물)] - Anon / 2002 / Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults / J Am Acad Child Adolesc Psychiatry 41 : 26 ~ 49
3. [학술지(정기간행물)] - Wilens T / 2003 / ADHD treatment with once-daily OROS methylphenidate:interim 12-month results from a long-term open-label study / J Am Acad Child Adolesc Psychiatry 42 : 424 ~ 433
4. [학술지(정기간행물)] - Kelly KL / 1988 / Attention deficit disorder and methylphenidate-a multi-step analysis of dose-response effects on childrens cardiovascular functioning / Int Clin Psychopharmacol 3 : 167 ~ 181
5. [학술지(정기간행물)] - Solanto MV / 1982 / A dose-response and time-action analysis of autonomic and behavioral-effects of methylphenidate in attention deficit disorder with hyperactivity / Psychophysiology 19 : 658 ~ 667
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
주의력결핍 과잉행동장애에서 오로스 메칠페니데이트의 효용성
소아청소년정신의학
2012 .10
-
Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate- OROS (OROS-MPH): A Multi-center, Open-label Study in Korea
Clinical Psychopharmacology and Neuroscience
2011 .01
-
Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
PSYCHIATRY INVESTIGATION
2012 .01
-
주의력결핍 과잉행동장애의 신경생물학과 오로스 메칠페니데이트의 작용기전
소아청소년정신의학
2012 .10
-
12주 OROS-Methylphenidate 약물 치료 후 ADHD 아동의 삶의 질 변화
소아청소년정신의학
2012 .09
-
Effect of Methylphenidate on Sleep Parameters in Children with ADHD
PSYCHIATRY INVESTIGATION
2012 .01
-
Multicenter, Open-Label Study to Evaluate the Effects of Methylphenidate-OROS(Concerta) on Cognitive Functions in Children with Attention Deficit Hyperactivity Disorder
Clinical Psychopharmacology and Neuroscience
2007 .01
-
주의력결핍 과잉행동장애에서 노르에피네프린 수송체 유전자와 오로스 메칠페니데이트 부작용의 연관성
소아청소년정신의학
2014 .06
-
The Effects of Methylphenidate on Neural Substrates Associated with Interference Suppression in Children with ADHD: A Preliminary Study Using Event Related fMRI
PSYCHIATRY INVESTIGATION
2010 .01
-
Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder
Yonsei Medical Journal
2009 .01
-
Differences in the Clinical Characteristics of Remission and Non-Remission Groups with Once-Daily OROS-Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder
Clinical Psychopharmacology and Neuroscience
2008 .01
-
주의력결핍과잉운동장애 아동에게 methylphenidate-OROS 투여시 효용성과 안전성 및 부모 만족도를 평가하기 위한 다기관관찰연구
소아청소년정신의학
2005 .09
-
Methylphenidate Induced Lip and Tongue Biting
Clinical Psychopharmacology and Neuroscience
2018 .01
-
Preliminary Investigation of Association between Methylphenidate and Serum Growth Markers in Children with Attention-Deficit/Hyperactivity Disorder: A Cross-Sectional Case-Control Study
소아청소년정신의학
2020 .07
-
New Option of ADHD Treatment: Combination with ATX and MPH
대한소아청소년정신의학회 학술대회논문집
2020 .07
-
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Cancer Research and Treatment
2014 .01
-
주의력결핍 과잉행동장애에서 오로스 메칠페니데이트의 내약성과 안전성
소아청소년정신의학
2012 .10
-
주의력 결핍 과잉 행동 환자에서 OROS-Methylphenidate 투여 후 신경심리학적 변화에 대한 개방 연구
소아청소년정신의학
2013 .09
-
Methylphenidate 투약에 따른 주의력결핍 과잉운동장애 아동의 정량화 뇌파의 변화
생물치료정신의학
2002 .06
-
주의력결핍과잉행동장애에서 Alpha-2A-Adrenergic 수용체 유전자와 Methylphenidate 반응과의 연관성에 대한 연구
신경정신의학
2011 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
주의력결핍 과잉행동장애에서 정신자극제를 이용한 약물치료
양영희
,
유희정
소아청소년정신의학
2008
.06
주의력결핍 과잉행동장애에서 파탄적 행동장애의 공존과 약물치료
강제욱
,
박은진
,
김성찬
외 5명
소아청소년정신의학
2012
.10
주의력결핍 과잉행동장애에서 비정신자극제 약물치료
황준원
소아청소년정신의학
2008
.06
성인 주의력결핍 과잉행동장애의 약물치료
양재원
,
김지훈
,
김재원
외 3명
소아청소년정신의학
2012
.10
주의력결핍 과잉행동장애 한국형 치료 권고안(III) : 약물치료
유희정
,
양수진
,
신동원
외 7명
소아청소년정신의학
2007
.04
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-516-000731280